A new drug candidate targeting E. coli in the gut is in phase 1 clinical trials. According to a new paper it may improve the well-being of blood cancer patients and reduce their mortality rate from E. coli infections.
from Top Technology News -- ScienceDaily https://ift.tt/bIYGX9O
from Top Technology News -- ScienceDaily https://ift.tt/bIYGX9O
Comments
Post a Comment